Transcode Therapeutics (RNAZ) Net Shares Issued and Repurchased (2020 - 2025)

Transcode Therapeutics (RNAZ) has reported Net Shares Issued and Repurchased for 6 consecutive years, with $67.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Net Shares Issued and Repurchased fell 96.81% year-over-year to $67.0; the trailing twelve-month figure through Dec 2025 stood at $67.0 (down 96.81% YoY), and the FY2025 full-year result was $67.0, down 96.81% from the prior year.
• Net Shares Issued and Repurchased declined to $67.0 in Q4 2025 per RNAZ's latest filing, from $464.0 in the prior quarter.
• Across five years, Net Shares Issued and Repurchased topped out at $453000.0 in Q1 2022 and bottomed at $67.0 in Q4 2025.
• Historically, Net Shares Issued and Repurchased has averaged $59806.4 across 5 years, with a median of $1425.0 in 2022.
• The sharpest annual moves came in 2022 and 2024: Net Shares Issued and Repurchased tumbled 97.82% in 2022, then jumped 2259.55% in 2024.
• Over 5 years, Net Shares Issued and Repurchased stood at $78979.0 in 2021, then sank by 97.82% to $1720.0 in 2022, then tumbled by 94.83% to $89.0 in 2023, then surged by 2259.55% to $2100.0 in 2024, then tumbled by 96.81% to $67.0 in 2025.
• According to Business Quant data, Net Shares Issued and Repurchased over the past three periods registered $67.0, $464.0, and $2100.0 for Q4 2025, Q1 2025, and Q4 2024 respectively.